Literature DB >> 22177720

Melatonin plus physical exercise are highly neuroprotective in the 3xTg-AD mouse.

Yoelvis García-Mesa1, Lydia Giménez-Llort, Luis C López, Carmen Venegas, Rosa Cristòfol, Germain Escames, Darío Acuña-Castroviejo, Coral Sanfeliu.   

Abstract

Alzheimer's disease (AD) is a devastating age-related neurodegenerative disease with no specific treatment at present. Several healthy lifestyle options and over-the-counter drugs that it has been suggested delay the onset of the disease are in an experimental phase, but it is unclear whether they will have any therapeutic value against AD. We assayed physical exercise and melatonin in 3xTg-AD male mice aged from 6 to 12 months, therefore from moderate to advanced phases of AD pathology. Analysis of behavior and brain tissue at termination showed differential patterns of neuroprotection for the 2 treatments. Both treatments decreased soluble amyloid β oligomers, whereas only melatonin decreased hyperphosphorylated tau. Melatonin was effective against the immunosenescence that 3xTg-AD mice present. Voluntary physical exercise protected against behavioral and psychological symptoms of dementia such as anxiety, a lack of exploration, and emotionality. Both treatments protected against cognitive impairment, brain oxidative stress, and a decrease in mitochondrial DNA (mtDNA). Interestingly, only the combined treatment of physical exercise plus melatonin was effective against the decrease of mitochondrial complexes. Therefore, melatonin plus physical exercise may exert complementary, additive, or even synergistic effects against a range of disturbances present in AD.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22177720     DOI: 10.1016/j.neurobiolaging.2011.11.016

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  23 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology.

Authors:  Neeraj Joshi; Joyshree Biswas; C Nath; Sarika Singh
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

3.  Autoimmune manifestations in the 3xTg-AD model of Alzheimer's disease.

Authors:  Monica Marchese; David Cowan; Elizabeth Head; Donglai Ma; Khalil Karimi; Vanessa Ashthorpe; Minesh Kapadia; Hui Zhao; Paulina Davis; Boris Sakic
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

4.  Resveratrol Induces Brain Resilience Against Alzheimer Neurodegeneration Through Proteostasis Enhancement.

Authors:  Rubén Corpas; Christian Griñán-Ferré; Eduard Rodríguez-Farré; Mercè Pallàs; Coral Sanfeliu
Journal:  Mol Neurobiol       Date:  2018-06-13       Impact factor: 5.590

Review 5.  Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neuromolecular Med       Date:  2018-03-23       Impact factor: 3.843

Review 6.  Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases.

Authors:  Lynn Marie Trotti; Elias G Karroum
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

7.  Regular exercise prevents non-cognitive disturbances in a rat model of Alzheimer's disease.

Authors:  An T Dao; Munder A Zagaar; Samina Salim; Jason L Eriksen; Karim A Alkadhi
Journal:  Int J Neuropsychopharmacol       Date:  2013-11-14       Impact factor: 5.176

Review 8.  Regulation of Melatonin and Neurotransmission in Alzheimer's Disease.

Authors:  Jaydeep Roy; Ka Chun Tsui; Jonah Ng; Man-Lung Fung; Lee Wei Lim
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

9.  Environmental enrichment eliminates the anxiety phenotypes in a triple transgenic mouse model of Alzheimer's disease.

Authors:  Susanna Pietropaolo; Joram Feldon; Benjamin K Yee
Journal:  Cogn Affect Behav Neurosci       Date:  2014-09       Impact factor: 3.526

10.  Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.

Authors:  Alan G Wade; Mildred Farmer; Gil Harari; Naama Fund; Moshe Laudon; Tali Nir; Anat Frydman-Marom; Nava Zisapel
Journal:  Clin Interv Aging       Date:  2014-06-18       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.